We are Dedicated to
Biopharmaceutical
Research & Advancement

What We Do
Generex Biotechnology Corp., is a biopharmaceutical company that is actively involved in discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies.
News

******To read the transcript of the January 4, 2018 Generex Investor Call please click here .******
  1. Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals
    January 2, 2018
    MIRAMAR, Florida, January 2, 2018 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today confirmed its receipt of the $700,000 USD up-front license fee (net of applicable Chinese withholding taxes) payable by Shenzhen BioScien Pharmaceuticals Co. Ltd. (www.BioScien.cn) under the License and Research Agreement entered into with Generex wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com). The purpose of the Agreement is to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).
    READ MORE
  2. Generex Provides Access Information for Investor Conference Call Scheduled for January 4, 2018
    January 3, 2018
    MIRAMAR, Florida, January 3, 2018 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer Joseph Moscato, and his management team, tomorrow, Thursday, January 4, 2018, at 10:30 a.m. Eastern time
    READ MORE
  3. Generex Announces Initial Pharmacy Acquisitions & Plans for Broader Acquisitions Strategy
    January 3, 2018
    MIRAMAR, Florida, January 3, 2018 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced that it has completed the acquisition of two pre-operational retail pharmacy operations.
    READ MORE
  4. Generex CEO Provides 2017 Year-End Summary to Stakeholders
    January 4, 2018.
    MIRAMAR, Florida, January 4, 2018 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today issued the following letter from the Company’s President & Chief Executive Officer, Joseph Moscato, providing his fellow stockholders with a summary of the Company’s initiatives and achievements over the course of 2017. This letter is being issued in advance of the Company’s investor conference call, to be hosted by Mr. Moscato, and his management team, today at 10:30 a.m. Eastern time
    READ MORE